89/100 A · Low risk
No major risk flags in public sources TraceComp due-diligence verdict — sanctions, screening, insolvency, control & financial signals combined.

✅ No sanctions, screening, insolvency or control red flags found in the public sources we cover. (Absence of a flag is not a guarantee — see methodology.)

THERAVECTYS

Active 5599 7219 Active for 21 years

5599 · RC 482324282 · Active since 2005

A

Overview

THERAVECTYS is a 5599 registered , France, since 2005. The company operates in the 7219 sector. With reported revenue of 253K EUR in 2024. Its TraceComp score of 89 (A) indicates solid fundamentals and low apparent risk. With 21 years of operations, the company has an established track record in its market.

Company Information

Registration Number
482324282
Legal Form
5599
Registered
2005-05-12

Financial Profile

Latest filed accounts: FY 2024

Revenue (2024) 253,195 EUR
Net Income -4,028,891 EUR
Total Assets 12,362,647 EUR
Altman Z 4.24 safe

Multi-year financials & ratios

5 years of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Officers & Management

9 officers/directors on file — names, roles, appointment & resignation dates.

NameRoleStatus
CHRISTIAN Brechot role 65 Current
+ 8 more in the full report

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Research Output

Active research organization. 179 publications · 10,361 citations · h-index 63 in the global scholarly record (OpenAlex — 82.9M papers). Top fields by publication volume: Medicine (42%) · Social Sciences (37%) · Biochemistry, Genetics and Molecular Biology (9%).

See full research profile — top researchers & publications →

Source: OpenAlex (CC0). Objective publication & citation counts.

Patent Portfolio

Active patent holder. 9 patents · 9 active · 9 granted in the USPTO/EPO record.

See full patent portfolio — most-cited inventions & inventors →

Source: USPTO / EPO open patent data. Objective bibliographic counts.

Risk Signals

No adverse legal events have been recorded for this company.

  • Revenue up 99% year-on-year
  • Net loss reported in FY 2024
  • Altman Z-Score in the safe zone

Data Sources & Freshness

Data sourced from: bulk register.